EP1620409B1 - Quinoxalin-3-one derivatives as orexin receptor antagonists - Google Patents

Quinoxalin-3-one derivatives as orexin receptor antagonists Download PDF

Info

Publication number
EP1620409B1
EP1620409B1 EP04729421A EP04729421A EP1620409B1 EP 1620409 B1 EP1620409 B1 EP 1620409B1 EP 04729421 A EP04729421 A EP 04729421A EP 04729421 A EP04729421 A EP 04729421A EP 1620409 B1 EP1620409 B1 EP 1620409B1
Authority
EP
European Patent Office
Prior art keywords
phenyl
methyl
ethyl
oxo
quinoxalin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04729421A
Other languages
German (de)
French (fr)
Other versions
EP1620409A1 (en
Inventor
Hamed Aissaoui
Martine Clozel
Thomas Weller
Ralf Koberstein
Thierry Sifferlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Priority to EP04729421A priority Critical patent/EP1620409B1/en
Priority claimed from PCT/EP2004/004374 external-priority patent/WO2004096780A1/en
Publication of EP1620409A1 publication Critical patent/EP1620409A1/en
Application granted granted Critical
Publication of EP1620409B1 publication Critical patent/EP1620409B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Definitions

  • the present invention relates to novel quinoxalinone derivatives of the general formula (I) and their use as pharmaceuticals.
  • the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula (I), and especially their use as orexin receptor antagonists.
  • the orexins comprise two neuropeptides produced in the hypothalamus: the orexin A (OX-A) (a 33 amino acid peptide) and the orexin B (OX-B) (a 28 amino acid peptide) ( Sakurai T. et al., Cell, 1998, 92, 573-585 ). Orexins are found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behaviour ( Sakurai T. et al., Cell, 1998, 92, 573-585 ).
  • orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches for narcoleptic patients ( Chemelli R.M. et al., Cell, 1999, 98, 437-451 ).
  • Two orexin receptors have been cloned and characterized in mammals. They belong to the super family of G-protein coupled receptors ( Sakurai T. et al., Cell, 1998, 92, 573-585 ): the orexin-1 receptor (OX 1 ) is selective for OX-A and the orexin-2 receptor (OX 2 ) is capable to bind OX-A as well as OX-B.
  • Orexin receptors are found in the mammalian brain and may have numerous implications in pathologies such as depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis; depressive neurosis; anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder; schizophrenia; manic depression; delirium; dementia; severe mental retardation and dyskinesias such as Huntington's disease and Tourette syndrome; eating disorders such as anorexia, bulimia, cachexia, and obesity; cardiovascular diseases; diabetes; appetite/taste disorders; vomiting/nausea; asthma; cancer; Parkinson's disease; Cushing's syndrome/disease; basophile adenoma; prolactinoma; hyperprolactinemia; hypophysis tumour/adenoma; hypothalamic diseases; inflammatory bowel disease; gastric diskinesia; gastric ulcers; Froehlich's syndrome; adrenohypophysis disease
  • HIV post-chemotherapy pain
  • post-stroke pain post-operative pain
  • neuralgia conditions associated with visceral pain such as irritable bowel syndrome, and angina
  • urinary bladder incontinence e.g. urge incontinence
  • tolerance to narcotics or withdrawal from narcotics sleep disorders; migraine; sleep apnea; narcolepsy; insomnia; parasomnia; jet-lag syndrome; and neurodegenerative disorders including nosological entities such as disinhibition-dementia-parkinsonism-amyotrophy complex; pallido-ponto-nigral degeneration epilepsy; seizure disorders and other diseases related to general orexin system dysfunction.
  • the present invention comprises quinoxalinone derivatives, which are non-peptide antagonists of the human orexin receptors.
  • quinoxalinone derivatives which are non-peptide antagonists of the human orexin receptors.
  • These compounds therefore, are of potential use in the treatment of disturbed homeostasis and eating disorders (e.g. bulimia, obesity, food abuse, compulsive eating) or irritable bowel syndrome, as well as disturbed sleep/wake schedule, sleep disorders (e.g. insomnias, apneas, dystonias) or stress-related diseases (e.g. anxiety, mood and blood pressure disorders) or any other diseases related to the orexin dysfunction.
  • eating disorders e.g. bulimia, obesity, food abuse, compulsive eating
  • irritable bowel syndrome e.g. irritable bowel syndrome
  • sleep disorders e.g. insomnias, apneas, dystonias
  • stress-related diseases e.g. anxiety, mood and blood pressure
  • the present invention relates to novel quinoxalinone derivatives of the general formula (I). wherein:
  • the compounds of formula (1) can contain one or more asymmetric centres and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixture of diastereoisomeric racemates, or meso forms md pharmaceutically acceptable salts thereof.
  • C 1 -C 5 alkyl signifies a straight-chain or branched-chain alkyl group with 1 to 5 carbon atoms.
  • straight-chain and branched C 1 -C 5 alkyl groups are methyl, ethyl, n-propyl, isopropyl, a-butyl, n-pentyl, isobutyl,sec-butyl, tert-butyl, the isomeric pentyls, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and n-pentyl.
  • C 2 -C 5 alkenyl signifies a straight-chain or branched-chain alkenyl group with 2 to 5 carbon atoms, preferably allyl and vinyl.
  • C 1 -C 5 alkoxy signifies a group of the general formula C 1 -C 5 -alkyl-O- in which "C 1 -C 5 -alkyl” has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy, preferably methoxy and ethoxy.
  • C 2 -C 5 alkenyloxy signifies a group of the general formula C 2 -C 5 -alkenyl-O- in which "C 2 -C 5 -alkenyl” has the previously given significance.
  • Preferred C 2 -C 5 alkenyloxy groups are vinyloxy and allyloxy.
  • cycloalkyl signifies a cycloalkyl ring with 3 to 8 carbon atoms and preferably a cycloalkyl ring with 3 to 6 carbon atoms.
  • Examples of C 3 -C 8 cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, preferably cyclopropyl, cyclohexyl or C 1 -C 5 alkyl substituted cycloalkyl such as methyl-cyclopropyl, dimethyl-cyclopropyl, methyl-cyclobutyl, methylcyclopentyl, methyl-cyclohexyl, or dimethyl-cyclohexyl.
  • aryl signifies a phenyl or naphthyl group which optionally carries one or more substituents, preferably one or two substituents, each independently selected from cyano, halogen, hydroxy, C 1 -C 5 alkyl, C 2 -C 5 alkenyl, C 1 -C 5 alkoxy, C 2 -C 5 alkenyloxy, nitro, trifluoromethyl, trifluoromethoxy, amino, carboxy, or alkoxycarbonyl such as phenyl, p-tolyl, 4-methoxyphenyl, 4-tert-butoxyphenyl, 4-fluorophenyl, 2-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl and 2-naphthyl.
  • Preferred are carboxyphenyl, C 1 -C 5 alkoxy-phenyl, hydroxyphenyl and particularly phenyl.
  • aralkyl signifies a C 1 -C 5 -alkyl or cycloalkyl group as previously defined in which one hydrogen atom has been replaced by an aryl group as previously defined.
  • Preferred are benzyl and benzyl substituted in the phenyl ring with hydroxy, C 1 -C 5 alkyl, trifluoromethyl, C 1 -C 5 alkoxy or halogen preferably fluorine. Particularly preferred is benzyl.
  • heterocyclyl and “heterocyclyl- C 1 -C 5 alkyl”
  • the heterocyclyl group is preferably a 5- to 10-membered monocyclic or bicyclic ring, which may be saturated, partially unsaturated or aromatic containing for example 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulphur which may be the same or different.
  • heterocyclyl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, thienyl, thiazolyl, isothiazolyl, furyl, imidazolyl, pyrazolyl, pyrrolyl, indazolyl, indolyl, isoindolyl, isoxazolyl, oxazolyl, quinoxalinyl, phthalazinyl, cinnolinyl, dihydropyrrolyl, pyrrolidinyl, isobenzofuranyl, tetrahydrofuranyl, dihydropyranyl.
  • the heterocyclyl group may have up to 5, preferably 1, 2 or 3 optional substituents.
  • suitable substituents include halogen, C 1 -C 5 alkyl, amino, nitro, cyano, hydroxy, C 1 -C 5 alkoxy, carboxy and C 1 -C 5 alkyloxy-carbonyls.
  • halogen signifies fluorine, chlorine, bromine or iodine and preferably chlorine and fluorine and particularly fluorine.
  • Preferred compounds are compounds of the general formula (I) wherein n is the integer 0, 1 or 2, m is the integer 0, 1 or 2, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 have the meaning given in the general formula (I) above and X represents oxygen and N-CN.
  • More preferred compounds of the general formula (I) are those wherein n is the integer 0, m is the integer 0, R 5 represents methyl, R 6 represents phenyl, R 1 , R 2 , R 3 , R 4 , R 7 , R 8 and R 9 have the meaning given in the formula (I) above and X represents oxygen.
  • the present invention encompasses physiologically usable or pharmaceutically acceptable salts of compounds of formula (I).
  • This encompasses salts with physiologically compatible mineral acids such as hydrochloric acid, sulphuric or phosphoric acid; or with organic acids such as formic acid, methanesulphonic acid, acetic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid and the like.
  • the compounds of formula (I) which are acidic can also form salts with physiologically compatible bases. Examples of such salts are alkali metal, alkali earth metal, ammonium and alkylammonium salts such as Na, K, Ca or tetraalkylammonium salt.
  • the present invention encompasses different solvation complexes of compounds of general formula (I).
  • the solvation can be effected in the course of the manufacturing process or can take place separately, e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of general formula (I).
  • the present invention further encompasses different morphological forms, e.g. crystalline forms, of compounds of general formula (I) and their salts and solvation complexes. Particular heteromorphs may exhibit different dissolution properties, stability profiles, and the like, and are all included in the scope of the present invention.
  • the compounds of formula (1) might have one or several asymmetric centres and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates and the meso-forms.
  • the compounds of general formula (I) and their pharmaceutically usable salts can be used as medicament for the treatment of diseases or disorders which are associated with a role of orexin comprising eating disorders, diabetes, prolactinoma, cardiovascular disorders, cancer, pain, narcolepsy, sleep disorders like insomnia, sleep apnea, parasomnia, depression, anxiety, addictions, schizophrenia, neurodegenerative disorders and dementia.
  • the compounds of general formula (I) can also be used in the preparation of a medicament for the treatment of disorders which are associated with a role of orexin, comprising eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders.
  • the compounds of general formula (I) and their pharmaceutically usable salts are particularly useful for the treatment of eating disorders and sleep disorders.
  • Preferred compounds of formula (I) have IC 50 values below 100 nM, particularly preferred compounds have IC 50 values below 10 nM which have been determined with the FLIPR (Fluorometric Imaging Plates Reader) method described in the beginning of the experimental section.
  • FLIPR Fluorometric Imaging Plates Reader
  • the compounds of general formula (I) may also be used in combination with other pharmacologically active compounds comprising other orexin receptor antagonists, with lipid lowering agents, with anorectic agents, with sleep inducing agents, with antidepressants or with other drugs beneficial for the prevention or treatment of disorders as above-mentioned.
  • the compounds of formula (I) and their pharmaceutically usable salts can be used as medicament (e.g. in the form of pharmaceutical preparations).
  • pharmaceutical compositions containing a compound of formula (I) and usual carrier materials and adjuvants thereof are also in the scope of the invention.
  • These pharmaceutical compositions containing one or more compounds of formula (I) are used for the treatment of disorders which are associated with the role of orexin, comprising eating disorders and sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders.
  • the pharmaceutical preparations can be administered enterally, such as orally (e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions), nasally (e.g.
  • the administration can also be effected parenterally, such as intramuscularly or intravenously (e.g. in the form of injection solutions), or topically, e.g. in the form of ointments, creams or oils.
  • the compounds of formula (I) and their pharmaceutically usable salts can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragées, and hard gelatine capsules.
  • Lactose, cornstarch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragées, and hard gelatine capsules.
  • Suitable adjuvants for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc.
  • Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.
  • Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.
  • Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.
  • the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilisers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants.
  • the compounds of formula (1) may also be used in combination with one or more other therapeutically useful substances.
  • Examples are anorectic drugs like fenfluramine and related substances; lipase inhibitors like orlistat and related substances; antidepressants like fluoxetine and related substances; anxiolytics like alprazolam and related substances; sleep-inducers like zopiclone and related substances; or any other therapeutically useful substance.
  • the therapeutically effective amount of a compound of formula (I) can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 mg to 1000 mg, especially about 50 mg to about 500 mg, comes into consideration.
  • the pharmaceutical preparations conveniently contain about 1 - 500 mg, preferably 5 - 200 mg of a compound of formula (I).
  • the invention also relates to a process for the manufacture of pharmaceutical compositions for the treatment of disorders associated with the role of orexin, eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders, containing one or more compounds of formula (I), or a pharmaceutically acceptable salt thereof, as active ingredients which process comprises mixing one or more active ingredient or ingredients with pharmaceutically acceptable excipients and adjuvants in a manner known per se.
  • the compounds of general formula (I) of the present invention are prepared according to the general sequence of reactions outlined in the schemes below, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X and n are as defined in general formula (I) above.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X and n are as defined in general formula (I) above.
  • any compound obtained with one or more optically active carbon atoms may be resolved into pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates and the meso-forms in a manner known per se.
  • the compounds obtained may also be converted into a pharmaceutically acceptable salt thereof in a manner known per se.
  • the compounds of general formula (I) may be prepared from the corresponding 1,2-phenylenediamine derivatives with the desired 2-oxo carboxylic acid at reflux in EtOH ( Lawrence D. S. et al., J.Med.Chem. 2001, 44, 4, 594-601 ; Bekerman D. G. et al., Journal of Heterocyclic Chem. 1992, 29, 1, 129-133 ). Subsequent alkylation with R 5 -I/ NaOH/ TBAB ( Abdel-Ghany H. et al., Synth. Commun., 1990, 20, 6, 893-900 ) or with R 5 -Cl/ NaOEt/ EtOH ( Hermecz I.
  • the OX 1 and OX 2 receptor antagonistic activity of the compounds of general formula (I) was determined in accordance with the following experimental method.
  • CHO cells expressing the human orexin-1 receptor or the human orexin-2 receptor are grown in culture medium (Ham F-12 with L-Glutamine) containing 300 ⁇ g/ml G418, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin and 10 % inactivated foetal calf serum (FCS).
  • culture medium Ham F-12 with L-Glutamine
  • FCS foetal calf serum
  • the cells were seeded at 80'000 cells / well into 96-well black clear bottom sterile plates (Costar) which had been precoated with 1% gelatine in Hanks' Balanced Salt Solution (HBSS). All reagents were from Gibco BRL.
  • the seeded plates are incubated overnight at 37°C in 5% CO 2 .
  • Human orexin-A as an agonist is prepared as 1 mM stock solution in methanol/ water (1:1), diluted in HBSS containing 0.1 % BSA and 2 mM HEPES for use in the assay at a final concentration of 10 nM.
  • Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 96-well plates, first in DMSO, then in HBSS containing 0.1 % bovine serum albumin (BSA) and 2 mM HEPES.
  • BSA bovine serum albumin
  • the 96-well plates are incubated for 60 min at 37° C in 5% CO 2 .
  • the loading solution is then aspirated and cells are washed 3 times with 200 ⁇ l HBSS containing 2.5 mM probenecid, 0.1 % BSA, 2 mM HEPES. 100 ⁇ l of that same buffer is left in each well.
  • antagonists are added to the plate in a volume of 50 ⁇ l, incubated for 20 min and finally 100 ⁇ l of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the fluorescence peak induced by 10 nM orexin-A with buffer in place of antagonist. For each antagonist, IC 50 value (the concentration of compound needed to inhibit 50 % of the agonistic response) is determined. The compounds exhibit as an average an antagonistic activity regarding the OX 1 and OX 2 receptor in the range of an IC 50 of 1 nM to 100 nM.
  • the objective of the present test is to record the circadian behavioral activity of rats after oral administration of a compound according to general formula (I) of the invention.
  • Psychitropic drugs such as antidepressants, antipsychotics, sleep inducers or psychostimulants are well known to reduce or enhance home cage activity and body temperature following oral administration to laboratory animals.
  • Thermoregulation is a complex process that contributes to homeostasis by coordinating metabolism, energy balance and behaviour. Body temperature changes with circadian behavioural activity and increases when locomotion increases. These two parameters were measured by telemetry in conscious freely moving Wistar rats. Anaesthetized animals were implanted, under aseptic conditions, with a body temperature/activity telemetric device into the peritoneal cavity. More than two weeks after the implantation of the telemetry system, data were collected at 5 minutes intervals during 96 hours. Hourly means were calculated for each rat.
  • the first 48 h were used as an internal control trace and drug effects were compared to vehicle placebo. This method is validated pharmacologically by measuring amplitude and time course of both hypoactivity and hypothermia induced by GABA-A receptor modulators such as zolpidem.

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  • The present invention relates to novel quinoxalinone derivatives of the general formula (I) and their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula (I), and especially their use as orexin receptor antagonists.
  • The orexins (hypocretins) comprise two neuropeptides produced in the hypothalamus: the orexin A (OX-A) (a 33 amino acid peptide) and the orexin B (OX-B) (a 28 amino acid peptide) (Sakurai T. et al., Cell, 1998, 92, 573-585). Orexins are found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behaviour (Sakurai T. et al., Cell, 1998, 92, 573-585). On the other hand, it was also proposed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches for narcoleptic patients (Chemelli R.M. et al., Cell, 1999, 98, 437-451). Two orexin receptors have been cloned and characterized in mammals. They belong to the super family of G-protein coupled receptors (Sakurai T. et al., Cell, 1998, 92, 573-585): the orexin-1 receptor (OX1) is selective for OX-A and the orexin-2 receptor (OX2) is capable to bind OX-A as well as OX-B.
  • Orexin receptors are found in the mammalian brain and may have numerous implications in pathologies such as depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis; depressive neurosis; anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder; schizophrenia; manic depression; delirium; dementia; severe mental retardation and dyskinesias such as Huntington's disease and Tourette syndrome; eating disorders such as anorexia, bulimia, cachexia, and obesity; cardiovascular diseases; diabetes; appetite/taste disorders; vomiting/nausea; asthma; cancer; Parkinson's disease; Cushing's syndrome/disease; basophile adenoma; prolactinoma; hyperprolactinemia; hypophysis tumour/adenoma; hypothalamic diseases; inflammatory bowel disease; gastric diskinesia; gastric ulcers; Froehlich's syndrome; adrenohypophysis disease; hypophysis disease; adrenohypophysis hypofunction; adrenohypophysis hyperfunction; hypothalamic hypogonadism; Kallman's syndrome (anosmia, hyposmia); functional or psychogenic amenorrhea; hypopituitarism; hypothalamic hypothyroidism; hypothalamic-adrenal dysfunction; idiopathic hyperprolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth deficiency; dwarfism; gigantism; acromegaly; disturbed biological and circadian rhythms; sleep disturbances associated with diseases such as neurological disorders, neuropathic pain and restless leg syndrome; heart and lung diseases, acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardinal infarction; ischemic or haemorrhagic stroke; subarachnoid haemorrhage; ulcers; allergies; benign prostatic hypertrophy; chronic renal failure; renal disease; impaired glucose tolerance; migraine; hyperalgesia; pain; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia, and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndrome I and II; arthritic pain; sports injury pain; pain related to infection e.g. HIV, post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; conditions associated with visceral pain such as irritable bowel syndrome, and angina; urinary bladder incontinence e.g. urge incontinence; tolerance to narcotics or withdrawal from narcotics; sleep disorders; migraine; sleep apnea; narcolepsy; insomnia; parasomnia; jet-lag syndrome; and neurodegenerative disorders including nosological entities such as disinhibition-dementia-parkinsonism-amyotrophy complex; pallido-ponto-nigral degeneration epilepsy; seizure disorders and other diseases related to general orexin system dysfunction.
  • Up to now some low molecular weight compounds are known which have a potential to antagonise either specifically OX1 or OX2, or both receptors at the same time. In WO 99/09024 , WO 99/58533 , WO 00/47576 , WO 00/47577 and WO 00/47580 formerly SmithKline Beecham reported phenylurea, phenylthiourea and cinnamide derivatives as OX1 selective antagonists. More recently WO 01/85693 from Banyu Pharmaceuticals has been published wherein N-acyltetrahydroisoquinoline derivatives are disclosed. 2-Amino-methylpiperidine derivatives ( WO 01/96302 ), 3-aminomethyl-morpholine derivatives ( WO 02/44172 ) and N-aroyl cyclic amines ( WO 02/090355 , WO 02/089800 and WO 03/051368 ) have been suggested by formerly SmithKline Beecham as orexin receptor antagonists. Related compounds are disclosed in WO 03/002559 , WO 03/002561 , WO 03/ 051873, WO 03/032991 and WO 03/041711 . Furthermore benzamide derivatives ( WO 03/037847 ) and ethylene diamine derivatives ( WO 03/051872 ) have been published by SmithKline Beecham. International patent applications WO 01/68609 and WO 02/051838 disclose 1,2,3,4-tetrahydroisoquinoline and novel benzazepine derivatives as orexin receptor antagonists.
  • The present invention comprises quinoxalinone derivatives, which are non-peptide antagonists of the human orexin receptors. These compounds, therefore, are of potential use in the treatment of disturbed homeostasis and eating disorders (e.g. bulimia, obesity, food abuse, compulsive eating) or irritable bowel syndrome, as well as disturbed sleep/wake schedule, sleep disorders (e.g. insomnias, apneas, dystonias) or stress-related diseases (e.g. anxiety, mood and blood pressure disorders) or any other diseases related to the orexin dysfunction.
  • The present invention relates to novel quinoxalinone derivatives of the general formula (I).
    Figure imgb0001
     wherein:
    • X is O, NH, N-CN;
    • n is the integer 0, 1, 2, 3;
    • m is the integer 0, 1, 2, 3;
    • R1, R2, R3, R4 independently represent cyano, halogen, hydrogen, hydroxyl, C1-C5 alkyl, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkenyloxy, trifluoromethoxy, cycloalkyloxy or R1 and R2 together as well as R2 and R3 together or R3 and R4 together may form with the phenyl ring to which they are attached, a five, six or seven-membered ring containing one or two oxygen atoms which are separated by at least one carbon atom;
    • R5 represents hydrogen, C1-C5 alkyl, C2-C5 alkenyl, cycloalkyl, cycloalkyl- C1-C5 alkyl, -(CH2)m-O-C1-C5 alkyl, -(CH2)m-COOH, -(CH2)m-CO2-C1-C5 alkyl, -(CH2)m-CONH2, -(CH2)m-CONH-C1-C5 alkyl, -CON-(C1-C5 alkyl)2, -(CH2)m-N-C1-C5 alkyl;
    • R6 represents hydrogen, C1-C5 alkyl, cycloalkyl, cycloalkyl-C1-C5 alkyl;
    • R7 represents hydrogen; C1-C5 alkyl; C2-C5 alkenyl; or mono-, di- or tri-substituted phenyl or phenyl-C1-C5 alkyl, whereby the subsituents independently are C1-C5 alkyl, C1-C5 alkoxy, C2-C5 alkenyl or halogen; -(CH2)m-OH; -(CH2)m-O-C1-C5 alkyl; -(CH2)m-CO2H; - (CH2)m-CO2-C1-C5 alkyl; -(CH2)m-CONH2; -(CH2)m-CONH-C1-C5 alkyl; -CON-(C1-C5 alkyl)2;
    • R8 represents unsubstituted phenyl; unsubstituted pyridyl; unsubstituted phenyl-C1-C5 alkyl; unsubstituted pyridyl-C1-C5 alkyl; or mono-, di- or tri-substituted phenyl, pyridyl, phenyl-C1-C5 alkyl or pyridyl-C1-C5 alkyl, whereby the substituents independently are C1-C5 alkyl, C1-C5 alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethoxy or halogen;
    • R9 represents C1-C5 alkyl, C2-C5 alkenyl, cycloalkyl, cycloalkyl-C1-C5 alkyl, unsubstituted phenyl-C1-C5 alkyl; or mono-, di- or tri-substituted phenyl or phenyl-C1-C5 alkyl, whereby the substituents independently are C1-C5 alkyl, C1-C5 alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethoxy or halogen;
  • The compounds of formula (1) can contain one or more asymmetric centres and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixture of diastereoisomeric racemates, or meso forms md pharmaceutically acceptable salts thereof.
  • In the present description the term "C1-C5 alkyl", alone or in combination, signifies a straight-chain or branched-chain alkyl group with 1 to 5 carbon atoms. Examples of straight-chain and branched C1-C5 alkyl groups are methyl, ethyl, n-propyl, isopropyl, a-butyl, n-pentyl, isobutyl,sec-butyl, tert-butyl, the isomeric pentyls, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and n-pentyl.
  • The term "C2-C5 alkenyl", alone or in combination, signifies a straight-chain or branched-chain alkenyl group with 2 to 5 carbon atoms, preferably allyl and vinyl.
  • The term "C1-C5 alkoxy", alone or in combination, signifies a group of the general formula C1-C5-alkyl-O- in which "C1-C5-alkyl" has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy, preferably methoxy and ethoxy.
  • The term "C2-C5 alkenyloxy", alone or in combination, signifies a group of the general formula C2-C5-alkenyl-O- in which "C2-C5-alkenyl" has the previously given significance. Preferred C2-C5 alkenyloxy groups are vinyloxy and allyloxy.
  • The term "cycloalkyl", alone or in combination, signifies a cycloalkyl ring with 3 to 8 carbon atoms and preferably a cycloalkyl ring with 3 to 6 carbon atoms. Examples of C3-C8 cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, preferably cyclopropyl, cyclohexyl or C1-C5 alkyl substituted cycloalkyl such as methyl-cyclopropyl, dimethyl-cyclopropyl, methyl-cyclobutyl, methylcyclopentyl, methyl-cyclohexyl, or dimethyl-cyclohexyl.
  • The term "aryl", alone or in combination, signifies a phenyl or naphthyl group which optionally carries one or more substituents, preferably one or two substituents, each independently selected from cyano, halogen, hydroxy, C1-C5 alkyl, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkenyloxy, nitro, trifluoromethyl, trifluoromethoxy, amino, carboxy, or alkoxycarbonyl such as phenyl, p-tolyl, 4-methoxyphenyl, 4-tert-butoxyphenyl, 4-fluorophenyl, 2-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl and 2-naphthyl. Preferred are carboxyphenyl, C1-C5 alkoxy-phenyl, hydroxyphenyl and particularly phenyl.
  • The term "aralkyl", alone or in combination, signifies a C1-C5 -alkyl or cycloalkyl group as previously defined in which one hydrogen atom has been replaced by an aryl group as previously defined. Preferred are benzyl and benzyl substituted in the phenyl ring with hydroxy, C1-C5 alkyl, trifluoromethyl, C1-C5 alkoxy or halogen preferably fluorine. Particularly preferred is benzyl.
  • For the term "heterocyclyl" and "heterocyclyl- C1-C5 alkyl", the heterocyclyl group is preferably a 5- to 10-membered monocyclic or bicyclic ring, which may be saturated, partially unsaturated or aromatic containing for example 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulphur which may be the same or different. Examples of such heterocyclyl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, thienyl, thiazolyl, isothiazolyl, furyl, imidazolyl, pyrazolyl, pyrrolyl, indazolyl, indolyl, isoindolyl, isoxazolyl, oxazolyl, quinoxalinyl, phthalazinyl, cinnolinyl, dihydropyrrolyl, pyrrolidinyl, isobenzofuranyl, tetrahydrofuranyl, dihydropyranyl. The heterocyclyl group may have up to 5, preferably 1, 2 or 3 optional substituents. Examples of suitable substituents include halogen, C1-C5 alkyl, amino, nitro, cyano, hydroxy, C1-C5 alkoxy, carboxy and C1-C5 alkyloxy-carbonyls.
  • The term "halogen" signifies fluorine, chlorine, bromine or iodine and preferably chlorine and fluorine and particularly fluorine.
  • The term "carboxy", alone or in combination, signifies a -COOH group. Preferred compounds are compounds of the general formula (I) wherein n is the integer 0, 1 or 2, m is the integer 0, 1 or 2, R1, R2, R3, R4, R5, R6, R7, R8 and R9 have the meaning given in the general formula (I) above and X represents oxygen and N-CN.
  • Other preferred compounds of the general formula (I) are those wherein n is the integer 0, m is the integer 0, R1, R2, R3, R4, R5, R6, R7, R8 and R9 have the meaning given in the formula (I) above and X represents oxygen.
  • More preferred compounds of the general formula (I) are those wherein n is the integer 0, m is the integer 0, R5 represents methyl, R6 represents phenyl, R1, R2, R3, R4, R7, R8 and R9 have the meaning given in the formula (I) above and X represents oxygen.
  • Examples of preferred compounds are:
    • 1-[1-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-(1-phenyl-ethyl)-3-(2-propylphenyl)-urea;
    • 3-Biphenyl-2-yl-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl]-1-[1-phenyl-ethyl)urea; 3-(2-Ethoxy-phenyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-(1-phenyl-ethyl)-urea;
    • 3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-((S)-1-phenyl-ethyl)-urea;
    • 3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-((R)-1-phenyl-ethyl)-urea;
    • 3-(2-Ethoxy-phenyl-1-(2-methoxy-(S)-1-phenyl-ethyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;
    • 3-(2-Ethoxy-phenyl-1-(2-methoxy-(R)-1-phenyl-ethyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;
    • (R)-2-{3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-ureido}-2-phenyl-acetamide;
    • (3-{1-[3-(Ethoxy-phenyl)-1-(1-phenyl-ethyl)-ureido]-ethyl}-2-oxo-2H-quinoxalin-1-yl)-acetic acid ethyl ester;
    • 2-{3-[3-(2-Ethoxy-phenyl)-1-(1-phenyl-ethyl)-ureidomethyl]-2-oxo-2H-quinoxalin-1yl]-acetamide;
    • 1-Benzyl-3-(2-ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-methyl)-urea;
    • 1-Benzyl-3-(2-ethoxy-phenyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;
    • 3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-methyl)-1-(1-phenylethyl)-urea;
    • (S)-3-(2-Ethoxy-phenyl)-1-(3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-(1-phenyl-ethyl)-urea;
    • 1-(6-Chloro-pyridin-3 ylmethyl)-3 (2-ethoxy-phenyl)-1-(4-methyl-3 -oxo-3,4-dihydro-quinoxalin-2ylmethyl)-urea;
    • (S)-3-(2-Ethoxy-phenyl)-1-(2-methoxy-1-phenyl-ethyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;
    • (R)-3-(2-Ethoxy-phenyl)-1-(2-methoxy-1-phenyl-ethyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;
    • 3-(2-Ethoxy-phenyl)-1-(2-hydroxy-(S)-1-phenyl-ethyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-urea;
    • 3-(2-Ethoxy-phenyl)-1-(2-methoxy-(S)-1-phenyl-ethyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-urea;
    • 3-(2-Ethoxy-phenyl)-1-(3-hydroxy-(S)-1-phenyl-propyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-urea;
    • 3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-((S)-2-phenyl-propyl)-urea;
    • 3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-[-1-(3-trifluoromethyl-phenyl)-ethyl]-urea;
    • 3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-[-1 -(4-trifluoromethyl-phenyl)-ethyl]-urea;
    • N-(2-Ethoxy-phenyl)-N'-[1-(-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl)-N'-1-phenyl-ethyl-cyanoguanidine.
  • The present invention encompasses physiologically usable or pharmaceutically acceptable salts of compounds of formula (I). This encompasses salts with physiologically compatible mineral acids such as hydrochloric acid, sulphuric or phosphoric acid; or with organic acids such as formic acid, methanesulphonic acid, acetic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid and the like. The compounds of formula (I) which are acidic can also form salts with physiologically compatible bases. Examples of such salts are alkali metal, alkali earth metal, ammonium and alkylammonium salts such as Na, K, Ca or tetraalkylammonium salt. For a comprehensive list see "Handbook of Pharmaceutical Salts", P.H. Stahl, C.G. Wermuth Eds., Wiley-VCH, Weinheim/Zurich 2002, p. 329-350. The compounds of formula (I) can also be present in the form of a zwitterion.
  • The present invention encompasses different solvation complexes of compounds of general formula (I). The solvation can be effected in the course of the manufacturing process or can take place separately, e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of general formula (I).
  • The present invention further encompasses different morphological forms, e.g. crystalline forms, of compounds of general formula (I) and their salts and solvation complexes. Particular heteromorphs may exhibit different dissolution properties, stability profiles, and the like, and are all included in the scope of the present invention.
  • The compounds of formula (1) might have one or several asymmetric centres and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates and the meso-forms.
  • The compounds of general formula (I) and their pharmaceutically usable salts can be used as medicament for the treatment of diseases or disorders which are associated with a role of orexin comprising eating disorders, diabetes, prolactinoma, cardiovascular disorders, cancer, pain, narcolepsy, sleep disorders like insomnia, sleep apnea, parasomnia, depression, anxiety, addictions, schizophrenia, neurodegenerative disorders and dementia.
  • The compounds of general formula (I) can also be used in the preparation of a medicament for the treatment of disorders which are associated with a role of orexin, comprising eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders.
  • The compounds of general formula (I) and their pharmaceutically usable salts are particularly useful for the treatment of eating disorders and sleep disorders.
  • Preferred compounds of formula (I) have IC50 values below 100 nM, particularly preferred compounds have IC50 values below 10 nM which have been determined with the FLIPR (Fluorometric Imaging Plates Reader) method described in the beginning of the experimental section.
  • The compounds of general formula (I) may also be used in combination with other pharmacologically active compounds comprising other orexin receptor antagonists, with lipid lowering agents, with anorectic agents, with sleep inducing agents, with antidepressants or with other drugs beneficial for the prevention or treatment of disorders as above-mentioned.
  • The compounds of formula (I) and their pharmaceutically usable salts can be used as medicament (e.g. in the form of pharmaceutical preparations). Hence, pharmaceutical compositions containing a compound of formula (I) and usual carrier materials and adjuvants thereof are also in the scope of the invention. These pharmaceutical compositions containing one or more compounds of formula (I) are used for the treatment of disorders which are associated with the role of orexin, comprising eating disorders and sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders.
    The pharmaceutical preparations can be administered enterally, such as orally (e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories). However, the administration can also be effected parenterally, such as intramuscularly or intravenously (e.g. in the form of injection solutions), or topically, e.g. in the form of ointments, creams or oils.
  • The compounds of formula (I) and their pharmaceutically usable salts can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragées, and hard gelatine capsules. Lactose, cornstarch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragées, and hard gelatine capsules. Suitable adjuvants for soft gelatine capsules, are, for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc. Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc. Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc. Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.
    Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilisers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. The compounds of formula (1) may also be used in combination with one or more other therapeutically useful substances. Examples are anorectic drugs like fenfluramine and related substances; lipase inhibitors like orlistat and related substances; antidepressants like fluoxetine and related substances; anxiolytics like alprazolam and related substances; sleep-inducers like zopiclone and related substances; or any other therapeutically useful substance.
    The therapeutically effective amount of a compound of formula (I) can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 mg to 1000 mg, especially about 50 mg to about 500 mg, comes into consideration. The pharmaceutical preparations conveniently contain about 1 - 500 mg, preferably 5 - 200 mg of a compound of formula (I).
    Further, the invention also relates to a process for the manufacture of pharmaceutical compositions for the treatment of disorders associated with the role of orexin, eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders, containing one or more compounds of formula (I), or a pharmaceutically acceptable salt thereof, as active ingredients which process comprises mixing one or more active ingredient or ingredients with pharmaceutically acceptable excipients and adjuvants in a manner known per se.
    The compounds of general formula (I) of the present invention are prepared according to the general sequence of reactions outlined in the schemes below, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and n are as defined in general formula (I) above. As the case may be any compound obtained with one or more optically active carbon atoms may be resolved into pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates and the meso-forms in a manner known per se.
  • The compounds obtained may also be converted into a pharmaceutically acceptable salt thereof in a manner known per se.
  • As shown in Scheme 1, the compounds of general formula (I) may be prepared from the corresponding 1,2-phenylenediamine derivatives with the desired 2-oxo carboxylic acid at reflux in EtOH (Lawrence D. S. et al., J.Med.Chem. 2001, 44, 4, 594-601; Bekerman D. G. et al., Journal of Heterocyclic Chem. 1992, 29, 1, 129-133). Subsequent alkylation with R5-I/ NaOH/ TBAB (Abdel-Ghany H. et al., Synth. Commun., 1990, 20, 6, 893-900) or with R5-Cl/ NaOEt/ EtOH (Hermecz I. et al., Heterocycles 1998, 48, 9, 1851-1866) followed by bromination leads to the corresponding bromo intermediate. A second alkylation with the corresponding primary amine yields the secondary amine which is then converted to the desired urea compound by reaction with a commercially available or synthetized isocyanate (Scheme 1) (March J. Advanced Organic Chemistry-Reactions, Mechanisms and Structure 1992, page 418, 4th edition, John Wiley & Sons).
    Figure imgb0002
     The compounds of general formula (I) may be also prepared from available 1-chloro-2-nitrobenzene derivatives (cf. Scheme 2 hereinafter). Amination under basic conditions followed by the hydrogenation of the resulting nitrobenzene derivative gives the desired aniline intermediate according to the method reported (see Obase H. et al., J. Heterocyclic Chem. 1983, 20, 565-573). This intermediate is then converted to the corresponding quinoxalinone derivative using the same conditions as described in Scheme 1.
    Figure imgb0003
     The compounds of general formula (1) wherein R6 is hydrogen may also be prepared by reductive amination of 3-formyl-quinoxalin-2-one derivatives (synthetized by oxidation of the corresponding 3-methyl-quinoxalin-2-one derivative with selenium dioxide according to Ismail M.F. et al., Ind. J. Chem. 1981, 20B, 5, 394-397 and Farghaly A.M. et al., Farmaco, 1990, 45, 4, 431-438) with synthetized or commercially available primary amines (Scheme 3). The resulting secondary amine intermediate is then converted to the desired quinoxalinone derivative using the same conditions as described in Scheme 1.
    Figure imgb0004
     The compounds of general formula (I) wherein R9 is aryl and X is N-CN (cyano-guanidine analogs) may be prepared from synthesized or commercially available isothiocyanate using known methods ( Poindexter G.S. et al., W098/ 54136 ; Atwal K.S. et al., Tetrahedron Letters, 1989, 30, 52, 7313-7316; Atwal K.S. et al., J. Med. Chem. 1995, 38, 1966-1973) (Scheme 4).
    Figure imgb0005
    • Experimental Section I. Biology Determination of OX1 and OX2 receptor antagonistic activities
  • The OX1 and OX2 receptor antagonistic activity of the compounds of general formula (I) was determined in accordance with the following experimental method.
    • Experimental method: 1. Intracellular calcium measurements
  • Chinese hamster ovary (CHO) cells expressing the human orexin-1 receptor or the human orexin-2 receptor, are grown in culture medium (Ham F-12 with L-Glutamine) containing 300 µg/ml G418, 100 U/ml penicillin, 100 µg/ml streptomycin and 10 % inactivated foetal calf serum (FCS).
  • The cells were seeded at 80'000 cells / well into 96-well black clear bottom sterile plates (Costar) which had been precoated with 1% gelatine in Hanks' Balanced Salt Solution (HBSS). All reagents were from Gibco BRL.
  • The seeded plates are incubated overnight at 37°C in 5% CO2.
  • Human orexin-A as an agonist is prepared as 1 mM stock solution in methanol/ water (1:1), diluted in HBSS containing 0.1 % BSA and 2 mM HEPES for use in the assay at a final concentration of 10 nM.
  • Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 96-well plates, first in DMSO, then in HBSS containing 0.1 % bovine serum albumin (BSA) and 2 mM HEPES.
  • On the day of the assay, 100 µl of loading medium (HBSS containing 1 % FCS, 2 mM HEPES, 5 mM probenecid (Sigma) and 3 µM of the fluorescent calcium indicator fluo-3 AM (1 mM stock solution in DMSO with 10% pluronic acid) (Molecular Probes) is added to each well.
  • The 96-well plates are incubated for 60 min at 37° C in 5% CO2. The loading solution is then aspirated and cells are washed 3 times with 200 µl HBSS containing 2.5 mM probenecid, 0.1 % BSA, 2 mM HEPES. 100 µl of that same buffer is left in each well.
  • Within the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices), antagonists are added to the plate in a volume of 50 µl, incubated for 20 min and finally 100 µl of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the fluorescence peak induced by 10 nM orexin-A with buffer in place of antagonist. For each antagonist, IC50 value (the concentration of compound needed to inhibit 50 % of the agonistic response) is determined. The compounds exhibit as an average an antagonistic activity regarding the OX1 and OX2 receptor in the range of an IC50 of 1 nM to 100 nM.
    • 2. In vivo assay: Spontaneous home cage activity and body temperature measured by radiotelemetry in laboratory rats:
  • The objective of the present test is to record the circadian behavioral activity of rats after oral administration of a compound according to general formula (I) of the invention.
  • Decreased home cage activity measured by telemetry in male Wistar rats was considered as an indication for sleep-inducing potential of a restricted number of quinoxalinone derivatives.
  • Psychotropic drugs such as antidepressants, antipsychotics, sleep inducers or psychostimulants are well known to reduce or enhance home cage activity and body temperature following oral administration to laboratory animals. Thermoregulation is a complex process that contributes to homeostasis by coordinating metabolism, energy balance and behaviour. Body temperature changes with circadian behavioural activity and increases when locomotion increases. These two parameters were measured by telemetry in conscious freely moving Wistar rats. Anaesthetized animals were implanted, under aseptic conditions, with a body temperature/activity telemetric device into the peritoneal cavity. More than two weeks after the implantation of the telemetry system, data were collected at 5 minutes intervals during 96 hours. Hourly means were calculated for each rat. The first 48 h were used as an internal control trace and drug effects were compared to vehicle placebo. This method is validated pharmacologically by measuring amplitude and time course of both hypoactivity and hypothermia induced by GABA-A receptor modulators such as zolpidem.
    • II. Chemistry
  • The following examples illustrate the preparation of pharmacologically active compounds of the invention. All temperatures are stated in °C.
  • All hydrochloride salts were prepared by dissolving the free base in dichloromethane Followed by treatment with an excess of ethereal HCl (2M).
    • A. Abbreviations
    • AcOEt
    Ethyl acetate
    AcOH
    Acetic acid
    BSA
    Bovine serum albumin
    br
    broad (NMR)
    CHO
    Chinese hamster ovary
    d
    doublet (NMR)
    DMAP
    4-(Dimethylamino)pyridine
    DMF
    Dimethylformamide
    DMSO
    Dimethyl sulfoxide
    EDC-HCl
    1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
    eq
    equivalent
    ES
    Electron spray
    EtOH
    Ethanol
    FC
    Flash chromatography
    FCS
    Fetal calf serum
    FLIPR
    Fluorescent imaging plate reader
    h
    hour
    HBSS
    Hank's balanced salt solution
    HEPES
    4-(2-Hydroxyethyl)-piperazine-1-ethanesulfonic acid
    m
    multiplet (NMR)
    MeCN
    Acetonitrile
    MeOH
    Methanol
    Min.
    minutes
    MS
    Mass spectroscopy
    NaOAc
    Sodium acetate
    NMR
    Nuclear magnetic resonance
    LC
    Liquid chromatography
    q
    quartet (NMR)
    Ra Ni
    Raney nickel
    Rt
    retention time
    rt
    room temperature
    s
    singlet (NMR)
    t
    triplet (NMR)
    TEA
    Triethylamine
    TFA
    Trifluoroacetic acid
    THF
    Tetrahydrofuran
    B. 1H-quinoxalin-2-one derivatives 1) General procedure:
  • A mixture of the 1,2-phenylene-diamine derivative (1 g) and the 2-oxo-carboxylic acid derivative (1 eq) in dry EtOH (35 mL) was stirred at reflux for 2 h under nitrogen. After cooling, the EtOH was evaporated to give a crude brown solid. Recrystallisation from EtOH gave the desired quinoxalin-2-one derivative.
    • a) 3-Ethyl-1-methyl-1H-quinoxalin-2-one
  • Figure imgb0006
     Reaction between N methyl-1,2-phenylene-diamine and 2-oxo-butyric acid gave after recrystallisation (EtOH) the title compound;
    LC-MS: Rt = 3.81min. m/z =189 (M + 1).
    1H-NUR (300MHz; CDCl3) δ= 1.35 (3H, t), 3.0 (2H, q), 3.7 (3H, s), 7.3 (2H, m), 7.5 (1H, t), 7.85 (1H, d).
    • b) 1,3- Dimethyl-1H-quinoxalin- 2-one
  • Figure imgb0007
     Reaction between N-methyl-1,2-phenylene-diamine and pyruvic acid gave after recrystallisation (EtOH) the title compound;
    LC-MS: Rt = 3.26 min. m/z = 175 (M + 1).
    1H-NMR (300MHz; CDCl3) δ = 2.6 (3H, s), 3.7 (3H, s), 7.3 (2H, m), 7.55 (1H, t), 7.8 (1H, d).
    • c) 3-Ethyl-1H-quinoxalin-2-one
  • Figure imgb0008
     Reaction between 1,2-phenylene-diamine and 2-oxo-butyric acid gave after recrystallisation (EtOH) the title compound as a brown solid;
    LC-MS: Rt = 3.36 min. m/z = 175 (M + 1).
    1H-NMR (300MHz; CDCl3) δ = 2.4 (3H, t), 3.1 (2H, q), 7.3 (2H, m), 7.5 (1H, t), 7.85 (1H, d).
    • d) 3-Methyl-1H-quinoxalin-2-one
  • Figure imgb0009
     Reaction between 1,2-phenylene-diamine and pyruvic acid gave after recrystallisation (EtOH) the title compound as a beige solid;
    LC-MS: Rt = 2.91 min. m/z = 161 (M + 1).
    1H-NNM (300MHz; DMSO-d6) δ = 2.4 (3H, s), 7.25 (2H, m), 7.45 (1H, m), 7.85 (1H, d), 12.25 (1H, br.s).
    • e) (3-Ethyl-2-oxo-2H-quinoxalin-1-yl)-acetic acid ethylester
  • Figure imgb0010
     A mixture of 3-ethyl-1H quinoxalin-2-one (1.6 g), ethyl chloroacetate (1.1 eq), NaOEt (1.leq) in dry EtOH (15 mL) was stirred at reflux for 16 h under nitrogen. After cooling, the reaction mixture was evaporated in vacuo to dryness, and the residue was dissolved in ether. The resulting solution was washed with saturated NaHCO3 solution, water, dried (anhydrous MgSO4), filtered and concentrated in vacuo to give a crude brown-orange solid.
    FC (AcOEt/ heptane: 7/3) gave the title compound as a brown solid.
    LC-MS: Rt = 2.91 min. m/z = 261 (M + 1).
    1H-NMR (300MHz; CDCl3) δ= 1.35 (6H, m), 3.00 (2H, q), 4.25 (2H, q), 5.00 (2H, s), 7.05 (1H, d), 7.35 (1H, t), 7.55(1H, t), 7.85 (1H, d).
    • 2) 3-Bromomethyl-1-methyl-1H quinoxalin-2-one
  • Figure imgb0011
  • To a mixture of a 1,3-dimethyl-1H-quinoxalin-2-one (1g), anhydrous sodium acetate (0.565 g) in glacial AcOH (10 mL) was added dropwise over 10 min. a solution of bromine (0.295 mL) in glacial AcOH (6 mL). The resulting mixture was stirred at rt under nitrogen for 2h; then water and CH2Cl2 was added successively. The aqueous layer was extracted once again with CH2Cl2, the combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue.
    FC (AcOEt/ heptane: 1/1) gave the title compound as a pink-orange solid.
    LC-MS: Rt = 3.91 min. m/z = 254 (M + 1).
    1H-NMR (300MHz; CDCl3) δ = 3.75 (3H, s), 4.7 (2H, s), 7.35 (2H, m), 7.6 (1H, m), 7.85 (1H, dd).
    • 3) 3-(1-Bromo-ethyl)-1-methyl-1H-quinoxalin-2-one
  • Figure imgb0012
  • To a mixture of a 3-ethyl-1-methyl-1H quinoxalin-2-one (1g) and anhydrous sodium acetate (0.523 g) in glacial AcOH (10 mL) was added dropwise over 10 min. a solution of bromine (0.273 mL) in glacial AcOH (6 mL). The resulting pale yellow suspension was stirred at rt under nitrogen for 2h, cooled to 0°C, filtered and washed with cold-water to give the title compound as a pale yellow solid.
    LC-MS: Rt = 3.91 min. m/z = 268 (M + 1).
    1H-NMR (300MHz; CDCl3) δ = 2.1 (3H, t), 3.75 (3H, s), 5.7 (1H, m), 7.35 (2H, m), 7.6 (1H, m), 7.85 (1H, dd).
    • 4) [3-(1-Bromo-ethyl)-2-oxo-2H quinoxalin-1-yl] acetic acid ethyl ester
  • Figure imgb0013
  • To a mixture of (3-ethyl-2-oxo-2H-quinoxalin-1-yl)-acetic acid ethylester (1g), and anhydrous sodium acetate (0.38 g) in glacial AcOH (10 mL) was added dropwise over 10 min. a solution of bromine (0.2 mL) in glacial AcOH (6 mL). The resulting pale yellow suspension was stirred at rt under nitrogen for 2h, combined with water/ CH2Cl2, the aqueous layer was extracted once again with CH2Cl2. The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue. FC (AcOEt/ n-heptane: 1/1) gave the title compound as beige solid.
    LC-MS: Rt = 2.91 min. m/z = 340 (M + 1).
    1H-NMR (300MHz; CDCl3) δ = 1.25 (3H, m), 2.1 (3H, d), 4.25 (2H, q), 5.9 (1H, d), 6.2 (1H, d), 6.7 (1H, q), 7.1 (1H, d), 7.35 (1H, t), 7.55 (1H, t), 7.9 (1H, d).
    • 5) 1-Methyl-3-[(R,S)-1-((S)-1-phenyl-ethylammo)-ethyl]-1H-quinoxalin-2-one
  • Figure imgb0014
  • A mixture of rac-3-(1-bromo-ethyl)-1-methyl-1H-quinoxalin-2-one (0.1 g), (S)-(-)-α-methylbenzyl amine (0.049 mL), and TEA (0.052 mL) in dry THF (1 mL) was stirred at reflux for 20 h under inert atmosphere. After cooling to rt, the reaction mixture was combined with water/ CH2Cl2, and the aqueous layer was extracted once again with CH2Cl2. The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as a brown-orange viscous oil.
    LC-MS: Rt = 0.71 min. m/z = 308 (M + 1).
    • 6) 1- Methyl-3-[(R,S)-1-((R)-1-phenyl-ethylamino)-ethyl]-1H-quinoxalin-2-one
  • Figure imgb0015
  • A mixture of rac-3-(1-bromo-ethyl)-1-methyl-1H-quinoxalin-2-one (0.1 g), (R)-(+)-α-methylbenzyl amine (0.049 mL), and TEA (0.052 mL) in dry THF (1 mL) was stirred at reflux for 20 h under inert atmosphere. After cooling to rt, the reaction mixture was combined with water/ CH2Cl2, and the aqueous layer was extracted once again with CH2Cl2. The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as an orange viscous oil.
    LC-MS: Rt = 0.71 min. m/z = 308 (M + 1).
    • 7) 1-Methyl-3-[1-(1-phenyl-ethylamino)-ethyl]-1H-quinoxalin-2-one (mixture of diastereoisomers).
  • Figure imgb0016
  • A mixture of rac-3-(1-bromo-ethyl)-1-methyl-1H-quinoxalin-2-one (0.1 g), DL (+/-)-α-methylbenzyl amine (0.049 mL), and TEA (0.052 mL) in dry THF (1 mL) was stirred at reflux for 20 h under inert atmosphere. After cooling to rt, the reaction mixture was combined with water/ CH2Cl2, and the aqueous layer was extracted once again with CH2Cl2. The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue.
    FC (CH2Cl2/ MeOH: 9/1) gave 0.09 g the title compound as an orange viscous oil.
    LC-MS: Rt = 0.65 and 0.71 min. m/z = 308 (M + 1).
    • 8) 3-(1-Benzylamino-ethyl)-1-methyl-1H-quinoxalin-2-one
  • Figure imgb0017
  • A mixture of 3-(1-bromo-ethyl)-1-methyl-1H-quinoxalin-2-one (0.1 g), benzylamine (0.041 mL), and TEA (0.052 mL) in dry THF (1 mL) was stirred at reflux for 20 h under inert atmosphere. After cooling to rt, the reaction mixture was combined with water/CH2Cl2, and the aqueous layer was extracted once again with CH2Cl2. The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as an orange viscous oil.
    LC-MS: Rt = 0.69 min. mlz = 294 (M + 1).
    • 9) 3-(Benzylamino-methyl)-1-methyl-1H-quinoxalin-2-one
  • Figure imgb0018
  • A mixture of 3-bromomethyl-1-methyl-1H quinoxalin-2-one (0.1 g), benzylamine (0.043 mL), and TEA (0.055 mL) in dry THF (1 mL) was stirred at reflux for 20 h under inert atmosphere. After cooling to rt, the reaction mixture was combined with water/ CH2Cl2, and the aqueous layer was extracted once again with CH2Cl2. The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as an orange viscous oil.
    LC-MS: Rt = 0.71 min. m/z = 280 (M + 1).
    • 10) (R)-1-methyl-3-[(1-phenyl-ethylamino)-methyl]-1H-quinoxalin-2-one
  • Figure imgb0019
  • A mixture of 3-bromomethyl-1-methyl-1H quinoxalin-2-one (0.1 g), (R)-(+)-α-methylbenzyl amine (0.05 mL), and TEA (0.055 mL) in dry THF (1 mL) was stirred at reflux for 20 h under inert atmosphere. After cooling to rt, the reaction mixture was combined with water/ CH2Cl2, and the aqueous layer was extracted once again with CH2Cl2. The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as an orange viscous oil.
    LC-MS: Rt = 0.69 min. mlz = 294 (M + 1).
    • 11) (S)-1-methyl-3-[(1-phenyl-ethylamino)-methyl]-1H-quinoxalin-2-one
  • Figure imgb0020
  • A mixture of 3-bromomethyl-1-methyl-1H quinoxalin-2-one (0.1 g), (S)-(-)-α-methylbenzyl amine (0.05 mL), and TEA (0.055 mL) in dry THF (1 mL) was stirred at reflux for 20 h under inert atmosphere. After cooling to rt, the reaction mixture was combined with water/ CH2Cl2, and the aqueous layer was extracted once again with CH2Cl2. The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as an orange viscous oil.
    LC-MS: Rt = 0.69 min. m/z = 294 (M + 1).
    • 12) 3-[(R,S)-1-(2-Methoxy-(S)-1-phenyl-ethylamino)-ethyl]-1-methyl-1H-quinoxalin-2-one
  • Figure imgb0021
  • A mixture of rac-3-(1-bromo-ethyl)-1-methyl-1H-quinoxalin-2-one (0.1 g), (S)-(+)-1-amino-1-phenyl-2-methoxyethane (57 mg, 1eq), and TEA (0.055 mL) in dry THF (2.5 mL) was stirred at reflux for 20 h under inert atmosphere. After cooling to rt, the reaction mixture was combined with water/ CH2Cl2, and the aqueous layer was extracted once again with CH2Cl2. The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as a brown- orange viscous oil.
    LC-MS: Rt 2.98 min. mlz = 338 (M + 1).
    • 13) 3-[(R,S)-1-(2-Methoxy-(R)-1-phenyl-ethylamino)-ethyl]-1-methyl-1H-quinoxalin-2-one
  • Figure imgb0022
  • A mixture of rac-3-(1-bromo-ethyl)-1-methyl-1H quinoxalin-2-one (0.1 g), (R)-(-)-1-amino-1-phenyl-2-methoxyethane (57 mg, 1eq), and TEA (0.055 mL) in dry THF (2.5 mL) was stirred at reflux for 20 h under inert atmosphere. After cooling to rt, the reaction mixture was combined with water/ CH2Cl2, and the aqueous layer was extracted once again with CH2Cl2. The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as a brown- orange viscous oil.
    LC-MS: Rt 2.98 min. m/z = 338 (M + 1).
    • 14) {2-Oxo-3-[1-(1-phenyl-ethylamino)-ethyl]-2H-quinoxalin-1-yl}-acetic acid ethylester (mixture of diastereoisomers)
  • Figure imgb0023
  • A mixture of [3-(1-bromo-ethyl)-2-oxo-2H-quinoxalin-1-yl] acetic acid ethyl ester (0.1 g), (D, L)-(+/-)-α-methylbenzylamine (35.8 mg, 1eq), and TEA (0.041 mL) in dry THF (2.5 mL) was stirred at reflux for 20 h under inert atmosphere. After cooling to rt, the reaction mixture was combined with water/ CH2Cl2, and the aqueous layer was extracted once again with CH2Cl2- The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as a brown- orange viscous oil.
    LC-MS: Rt 0.76 min. m/z = 380 (M + 1).
    • 5) (R)-2-[(R,S)-1-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethylamino]-2-phenyl-acetamide
  • Figure imgb0024
  • A mixture of 3-(1-bromo-ethyl)-l-methyl-IH-quinoxalin-2-one (0.1 g), (R)-(-)-2-phenylglycine amide (57 mg, 1 eq), and TEA (0.055 mL) in dry THF (2.5 mL) was stirred at reflux for 20 h under inert atmosphere. After cooling to rt, the reaction mixture was combined with water/ CH2Cl2, and the aqueous layer was extracted once again with CH2Cl2. The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated to give a crude brown-orange residue.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as a pale brown viscous oil.
    LC-MS: Rt 2.70 min. m/z = 337 (M + 1).
    • 16) 3-Oxo-3,4-dihydro-quinoxaline-2-carbaldehyde
  • Figure imgb0025
  • A mixture of 3-methyl-1H-quinoxalin-2-one (0.5 g) and selenium dioxide (0.728 g, 2.1 eq) in dry dioxane (33 mL) was stirred at reflux under nitrogen for 30 min. After cooling, the dark-brown mixture was concentrated under reduced pressure and the residue was purified by FC (AcOEt) to give the title compound as an orange solid.
    1H-NMR (300MHz; DMSO-d6) δ = 7.35 (2H, m), 7.7 (1H, t), 7.9 (1H, d), 10.2 (1H, s), 12.8 (1H,br.s).
    • 17) 4-Methyl-3-oxo-3,4-dihydro-quinoxaline-2-carbaldehyde
  • Figure imgb0026
  • A mixture of 1,3-dimethyl-1H-quinoxalin-2-one (1g) and selenium dioxide (1.33 g, 2.1 eq) in dry dioxane (60 mL) was stirred at reflux under nitrogen for 30 min. After cooling, the dark-brown mixture was concentrated under reduced pressure and the residue was purified by FC (AcOEt) to give the title compound as a yellow solid.
    1H-NMR (300MHz; DMSO-d6 ) δ = 3.8 (3H, s), 7.35-7.45 (2H, m), 7.7 (1H, t), 8.1(1H, d), 10.5 (1H, s).
    • 18) (S)-3-[(1-Phenyl-ethylamino)-methyl]-1H-quinoxalin-2-one
  • Figure imgb0027
  • A mixture of 3-oxo-3,4-dihydro-quinoxaline-2-carbaldehyde (0.1 g), sodium triacetoxyborohydride (0.182 g, 1.5 eq), and (S)-(-)-α-methylbenzyl amine (70 mg) in dry CH2Cl2 (1.2 mL) was stirred at rt under nitrogen for 20h. The reaction mixture was then poured into water, extracted CH2Cl2. The combined organic extracts were dried (MgSO4) filtered and concentrated in vacuo to give a crude oil.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as brown oil.
    LC-MS: Rt = 0.66 min. m/z = 280 (M + 1).
    • 19) 3-{[(6-Chloro-pyridin-3-ylmethyl)-amino-methyl)}-1-methyl-1H-quinoxalin-2-one
  • Figure imgb0028
  • A mixture of 4-methyl-3-oxo-3,4-dihydro-quinoxaline-2-carbaldehyde (0.1 g), sodium triacetoxyborohydride (0.170 g, 1.5 eq), and 2-chloro-5-aminomethylpyridine (0.076 g, 1eq) in dry CH2Cl2 (1.5 mL) was stirred at rt under nitrogen for 1 day. The orange reaction mixture was basified with a sat. NaHCO3 solution, extracted CH2Cl2. The combined organic extracts were dried (MgSO4) filtered and concentrated in vacuo to give a crude oil.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as an orange oil.
    LC-MS: Rt = 2.93 min. m/z = 315 (M + 1).
    • 20) (S)-3-[(2-Hydroxy-1-phenyl-ethylamino)-methyl]-1-methyl-1H-quinoxalin-2-one
  • Figure imgb0029
  • A mixture of 4-methyl-3-oxo-3,4-dihydro-quinoxaline-2-carbaldehyde (0.1 g), sodium cyanoborohydride (0.05 g, 1.5 eq), and L-(+)-α-phenylglycinol (73 mg) in dry CH2Cl2 (1.5 mL) was stirred at rt under nitrogen for 15h. The reaction mixture was basified with a sat. NaHCO3 solution, extracted CH2Cl2. The combined organic extracts were dried (MgSO4) filtered and concentrated in vacuo to give a crude oil.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as a brown solid.
    LC-MS: Rt = 0.66 min. m/z = 310 (M + 1).
    • 21) (S)-3-[(-2-Methoxy-1-phenyl-ethylamino)-methyl]-1-methyl-1H-quinoxalin-2-one
  • Figure imgb0030
  • A mixture of 4-methyl-3-oxo-3,4-dihydro-quinoxaline-2-carbaldehyde (0.1 g), sodium cyanoborohydride (0.05 g, 1.5 eq), and (R)-(-)-1-amino-1-phenyl-2-methoxyethane (72 mg) in dry CH2Cl2 (1.5 mL) was stirred at rt under nitrogen for 16h. The reaction mixture was basified with a sat. NaHCO3 solution, extracted CH2Cl2. The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo to give a crude oil.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as a brown oil.
    LC-MS: Rt = 0.72 min. m/z = 324 (M + 1).
    • 22) (S)-1-Methyl-3-[(2-phenyl-propylamino)-methyl]-1H-quinoxalin-2-one
  • Figure imgb0031
  • A mixture of 4-methyl-3-oxo-3,4-dihydro-quinoxaline-2-carbaldehyde (0.1 g), sodium cyanoborohydride (0.05 g, 1.5 eq), and (S)-2-phenyl-1-propylamine (80 mg) in dry CH2Cl2 (1.5 mL) was stirred at rt under nitrogen for 16h. The reaction mixture was basified with a sat. NaHCO3 solution, extracted CH2Cl2. The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo to give a crude oil.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as a brown oil.
    LC-MS: Rt = 0.75 min. m/z = 308 (M + 1).
    • 23) (S)-3-[(-3-Hydroxy-1-phenyl-propylaniino)-methyl]-1-methyl-1H-quinoxalin-2-one
  • Figure imgb0032
  • A mixture of 4-methyl-3-oxo-3,4-dihydro-quinoxaline-2-carbaldehyde (0.08 g), sodium cyanoborohydride (0.04 g, 1.5 eq), and (S)-3-amino-3-phenyl-propan-1-ol (65 mg) in dry CH2Cl2 (2 mL) was stirred at rt under nitrogen for 16h. The reaction mixture was basified with a sat. NaHCO3 solution, extracted CH2Cl2. The combined organic extracts were dried (MgSO4) filtered and concentrated in vacuo to give a crude oil.
    FC (CH2Cl2/ MeOH: 9/1) gave the title compound as a yellow oil.
    LC-MS: Rt = 0.64 min. m/z = 324 (M + 1).
    • 24) 1-Methyl-3-{[1-(3-trifluoromethyl-phenyl)-ethylamino]-methyl}-1H-quinoxalin-2-one (racemate).
  • Figure imgb0033
  • A mixture of 4-methyl-3-oxo-3,4-dihydro-quinoxaline-2-carbaldehyde (63.6 mg), sodium cyanoborohydride (0.032 g, 1.5 eq), and 1-(3-trifluoromethyl-phenyl)-ethylamine (64 mg) (Ho B. et al. Eur. J. Med. Chena. 2001, 36, 3, 265-286) in dry CH2Cl2 (1.5 mL) was stirred at rt under nitrogen for 16h. The reaction mixture was basified with a sat. NaHCO3 solution, extracted CH2Cl2. The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo to give a crude oil.
    FC (CH2Cl2/ MeOH: 95/5) gave the title compound as a brown oil.
    LC-MS: Rt = 0.78 min. m/z = 362 (M + 1).
    • 25) 1-Methyl-3-{[1-(4-trifluoromethyl-phenyl)-ethylamino]-methyl}-1H-quinoxalin-2-one (racemate).
  • Figure imgb0034
     A mixture of 4-methyl-3-oxo-3,4-dihydro-quinoxaline-2-carbaldehyde (100 mg), sodium cyanoborohydride (0.050 g, 1.5 eq), and 1-(4-trifluoromethyl-phenyl)-ethylamine (100 mg) in dry CH2Cl2 (1.5 mL) was stirred at rt under nitrogen for 16h. The reaction mixture was basified with a sat. NaHCO3 solution, extracted CH2Cl2- The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo to give a crude oil.
    FC (CH2Cl2/ MeOH: 95/5) gave the title compound as a brown oil.
    LC-MS: Rt = 0.77 min. m/z = 362 (M + 1).
    • Example 1 3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-((S)-1- phenyl-ethyl)-urea
  • Figure imgb0035
  • To a solution of 1-methyl-3-[(R,S)-1-((S)-1-phenyl-ethylamino)-ethyl]-1H-quinoxalin-2-one (50 mg, 0.163 mmol) in dry CHCl3 (1 mL), was added 2-ethoxyphenyl isocyanate (26.3 mg, 0.163 mmol). The resulting reaction mixture was stirred at 50°C under nitrogen for 20h. The reaction mixture was then concentrated under reduced pressure and the residue was purified by FC (CH2Cl2/ MeOH: 19/ 1) to give the title compound as a yellow foam.
    LC-MS: Rt = 1.03 min. m/z = 471 (M + 1).
    • Example 2 3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-((R)-1-phenyl-ethyl)-urea
  • Figure imgb0036
  • In analogy to example 1 using 1- Methyl-3-[(R,S)-1-((R)-1-phenyl-ethylamino)-ethyl]-1H-quinoxalin-2-one (1 eq).
    FC (CH2Cl2/ MeOH: 19/ 1) afforded the title compound as a yellow oil.
    LC-MS: Rt = 1.03 min. mlz = 471 (M + 1).
    • Example 3 (R,S)-1-Benzyl-3-(2-ethoxy-phenyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea
  • Figure imgb0037
  • In analogy to example 1 using 3-(1-benzylamino-ethyl)-1-methyl-1H-quinoxalin-2-one (1 eq).
    FC (CH2Cl2/ MeOH: 19/ 1) afforded the title compound as a brown-orange oil.
    LC-MS: Rt = 1.01 min. m/z = 457 (M + 1).
    • Example 4 1-Benzyl-3-(2-ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-urea
  • Figure imgb0038
  • In analogy to example 1 using 3-(benzylamino-methyl)-1-methyl-1H quinoxalin-2-one (1 eq).
    FC (CH2Cl2 MeOH: 19/ 1) afforded the title compound as an orange oil.
    LC-MS: Rt = 0.98 min. m/z = 443 (M + 1).
    • Example 5 (R)-3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylmethyl)-1-(1-phenyl-ethyl)-urea
  • Figure imgb0039
  • In analogy to example 1 using (R)-1-methyl-3-[(1-phenyl-ethylamino)-methyl]-1H-quinoxalin-2-one (1 eq).
    FC (CH2Cl2/ MeOH: 19/1) afforded the title compound as an orange oil.
    LC-MS: Rt = 1.00 min. m/z = 457 (M + 1).
    • Example 6 (S)-3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2ylmethyl)-1-(1-phenyl-ethyl)-urea
  • Figure imgb0040
  • In analogy to example 1 using (S)-1-methyl-3-[(1-phenyl-ethylamino)-methyl]-1H-quinoxalin-2-one (1 eq).
    FC (CH2Cl2/ MeOH: 19/ 1) afforded the title compound as an orange oil.
    LC-MS: Rt = 1.00 min. mlz = 457 (M + 1).
    • Example 7 (S)-3-(2-Ethoxy-phenyl)-1-(3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-(1-phenylethyl)-urea
  • Figure imgb0041
  • In analogy to example 1 using (S)-3-[(1-phenyl-ethylamino)-methyl]-1H quinoxalin-2-one (1eq)
    FC (CH2Cl2 MeOH: 9/ 1) afforded the title compound as a pale-yellow solid.
    LC-MS: Rt = 0.94 min. m/z = 443 (M + 1),
    • Example 8 1-(6-Chloro-pyridin-3ylmethyl)-3-(2-ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-methyl)-urea
  • Figure imgb0042
  • In analogy to example 1 using the 3-{[(6-chloro-pyridin-3-ylmethyl)-amino-methyl]}-1-methyl-1H-quinoxalin-2-one (1eq)
    FC (CH2Cl2/ MeOH: 9/ 1) afforded the title compound as a yellow foam.
    LC-MS: Rt = 4.86 and 5.41 min. m/z = 478 (M + 1).
    • Example 9 (R)-2-{3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-ureido}-2-phenyl-acetamide.
  • Figure imgb0043
  • In analogy to example 1 using (R)-2-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethylamino]-2-phenyl-acetamide (1eq).
    FC (AcOEt/ heptane: 7/3) afforded the title compound as white foam.
    LC-MS: Rt = 4.63 min. m/z = 500 (M + 1).
    • Example 10 (3-{1-[3-(Ethoxy-phenyl)-1-(1-phenyl-ethyl)-ureido]-ethyl]-2-oxo-2H-quinoxalin-1-yl)-acetic acid ethyl ester (mixture of diastereoisomers)
  • Figure imgb0044
  • In analogy to Example 1 using (2-Oxo-3-[1-(1-phenyl-ethylamino)-ethyl]-2H-quinoxalin-1-yl}-acetic acid ethylester (1 eq).
    FC (AcOEt/ heptane: 3/7) afforded the title compound as an orange oil.
    LC-MS: Rt = 0.95 min. m/z = 543 (M + 1).
    • Example 11 2-(3-{1-[3-(2-Ethoxy-phenyl)-1-(1-phenyl-ethyl)-ureido]-ethyl}-2-oxo-2H-quinoxalin-1yl)-acetamide (mixture of diastereoisomers)
  • Figure imgb0045
  • A mixture of (3-{1-[3-(2-ethoxy-phenyl)-1-(1-phenyl-ethyl)-ureido]-ethyl}-2-oxo-2H-quinoxalin-1-yl)-acetic acid ethyl ester (0.11 g), and aqueous NaOH 2N (0.5 mL, 5 eq) in a mixture MeOH/ dioxane (4/3) (1.7 mL) was stirred at rt for 20 h. Then the reaction mixture was combined with water/ AcOEt, the aqueous layer was acidified until pH 1-2 with aqueous HCl 2N, and extracted with CH2Cl2 (three times). The combined organic extracts were dried (anhydrous MgSO4), filtered and concentrated in vacuo to give the crude acid as a white foam (0.09 g, 85%). To this crude acid (0.05 g) in dry CH2Cl2 (1.4 mL), were added successively EDC-HCl (0.026 g, 1eq), DMAP (0.035 g, 3eq), and a solution of ammonia (0.5 N in dioxane) (0.20 mL, 1eq). The resulting mixture was stirred at rt under nitrogen for 20 h. The mixture was then combined with CH2Cl2/ aqueous HCl 2N. The organic layer was washed twice with water, dried (anhydrous MgSO4), filtered and concentrated in vacuo to give a crude oil.
    FC (CH2Cl2/ MeOH: 9/ 1) afforded the title compound as a beige foam.
    LC-MS: Rt = 0.91 min. m/z = 514 (M +1).
    • Example 12 3-(2-Ethoxy-phenyl)-1-((R)-2-methoxy-1-phenyl-ethyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea
  • Figure imgb0046
  • In analogy to example 1 using 3-[(R,S)-1-(2-methoxy-(R)-1-phenyl-ethylamino)-ethyl]-1-methyl-1H-quinoxalin-2-one (1eq).
    FC (AcOEt/ heptane: 1/1) afforded the title compound as a pale brown oil.
    LC-MS: Rt = 5.27 min. mlz = 501 (M + 1).
    • Example 13 3-(2-Ethoxy-phenyt)-1-((S)-2-methoxy-1-phenyt-ethyl)-l-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea
  • Figure imgb0047
  • In analogy to example 1 using 3-[(R,S)-1-(2-methoxy-(S)-1-phenyl-ethylamino)-ethyl]-1-methyl-1H quinoxalin-2-one (1eq).
    FC (AcOEt/ heptane: 1/1) afforded the title compound as a pale brown oil.
    LC-MS: Rt = 5.28 min. mlz = 501 (M + 1).
    • Example 14 3-(2-Ethoxy-phenyl)-1-((S)-2-hydroxy-1-phenyt-ethyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-methyl)-urea
  • Figure imgb0048
  • In analogy to example 1 using (S)-3-[(-2-hydroxy-1-phenyl-ethylamino)-methyl]-1-methyl-1H quinoxalin-2-one (1eq).
    FC (CH2Cl2/ MeOH: 9/1) afforded the title compound as a yellow foam.
    LC-MS: Rt = 0.93 min. mlz = 473 (M + 1).
    • Example 15 3-(2-Ethoxy-phenyl)-1-((S)-2-methoxy-1-phenyl-ethyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-methyl)-urea
  • Figure imgb0049
  • In analogy to example 1 using (S)-3-[(-2-methoxy-1-phenyl-ethylamino)-methyl]-1-methyl-1H- quinoxalin-2-one (1eq).
    FC (heptane/ AcOEt: 3/7) afforded the title compound as a yellow foam.
    LC-MS: Rt = 1.00 min. m/z = 487 (M + 1).
    • Example 16 3-(2-Ethoxy-phenyl)-1-(3-hydroxy-(S)-1-phenyl-propyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-methyl)-urea
  • Figure imgb0050
  • In analogy to example 1 using (S)-3-[(-3-hydroxy-1-phenyl-propylamino)-methyl]-1-methyl-1H-quinoxalin-2-one (1eq).
    FC (CH2Cl2/ MeOH: 9/1) afforded the title compound as a yellow foam.
    LC-MS: Rt = 0.95 min. m/z = 487 (M + 1).
    • Example 17 3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-((S)-2-phenyl-propyl)-urea
  • Figure imgb0051
  • In analogy to example 1 using (S)-1-methyl-3-[(2-phenyl-propylamino)-methyl]-1H-quinoxalin-2-one (1eq).
    FC (Heptane/ AcOEt: 3/7) afforded the title compound as a yellow foam.
    LC-MS: Rt = 1.03 min. m/z = 471 (M + 1).
    • Example 18 3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-[-1-(3-trifluoromethyl-phenyl)-ethyl]-urea (racemate)
  • Figure imgb0052
  • In analogy to example 1 using 1-methyl-3-1[1-(3-trifluoromethyl-phenyl)-ethylamino]-methyl}-1H-quinoxalin-2-one (1eq).
    FC (Heptane/ AcOEt: 3/7) afforded the title compound as a brown oil.
    LC-MS: Rt = 1.07 min. m/z = 525 (M + 1).
    • Example 19 3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-[-1-(4-trifluoromethyl-phenyl)-ethyl]-urea (racemate)
  • Figure imgb0053
  • In analogy to example 1 using 1-methyl-3-{[1-(4-trifluoromethyl-phenyl)-ethylamino]-methyl}-1H- quinoxalin-2-one (1eq).
    FC (Heptane/ AcOEt: 3/7) afforded the title compound as a brown oil.
    LC-MS: Rt = 1.07 min. m/z= 525 (M + 1). (1eq).
    • Example 20 N-(2-Ethoxy-phenyl)-N-[1-(-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-ethyl)-]-N'-(1-phenyl-ethyl)-cyanoguanidine (mixture of diastereoisomers)
  • Figure imgb0054
  • A mixture of 2-ethoxyphenyl isothiocyanate (0.1 g) and sodium hydrogencyanamide (35.7 mg, 1eq) in dry EtOH (2 mL) was stirred at reflux under nitrogen for 3 h. After cooling to rt, EDC-HCl (0. 107 g, 1eq) and a solution of 1-methyl-3-[1-(1-phenyl-ethylamino)-ethyl]-1H-quinoxalin-2-one (0.172 g, 1eq) in dry DMF (1 mL) were added and the resulting reaction mixture was stirred at rt under nitrogen for 20 hours. The mixture was then combined with AcOEt and sat. NaHCO3, the aqueous layer was extracted once with AcOEt. The combined organic extracts were washed with brine, dried (anhydrous MgSO4), filtered and concentrated to give a crude pale-brown oil.
    FC (AcOEt/ heptane: 7/3) gave the title compound as a white solid.
    LC-MS: Rt = 5.26 min. m/z = 495 (M + 1).

Claims (9)

  1. Compounds of the general formula (I)
    Figure imgb0055
     wherein:
    X is O, NH, N-CN;
    n is the integer 0, 1, 2, 3;
    m is the integer 0,1,2,3;
    R1, R2, R3, R4 independently represent cyano, halogen, hydrogen, hydroxyl, C1-C5 alkyl, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkenyloxy, trifluoromethoxy, cycloalkyloxy or R1 and R2 together as well as R2 and R3 together or R3 and R4 together may form with the phenyl ring to which they are attached, a five, six or seven-membered ring containing one or two oxygen atoms which are separated by at least one carbon atom;
    R5 represents hydrogen, C1-C5 alkyl, C2-C5 alkenyl, cycloalkyl, cycloalkyl- C1-C5 alkyl, -(CH2)m-O-C1-C5 alkyl, -(CH2)m-COOH, -(CH2)m-CO2-C1-C5 alkyl, -(CH2)m-CONH2, -(CHz)m,CONH-C1-C5 alkyl, -CON-(C1-C5 alkyl)2, -(CH2)m-N-C1-C5 alkyl;
    R6 represents hydrogen, C1-C5 alkyl, cycloalkyl, cycloalkyl-C1-C5 alkyl;
    R7 represents hydrogen; C1-C5 alkyl; C2-C5 alkenyl; or mono-, di- or tri-substituted phenyl or phenyl-C1-C5 alkyl, whereby the subsituents independently are C1-C5 alkyl, C1-C5 alkoxy, C2-C5 alkenyl or halogen; -(CH2)m-OH; -(CH2)m-O-C1-C5 alkyl; -(CH2)m-CO2H; -(CH2)m-CO2-C1-C5 alkyl-, -(CH2)m-CONH2; -(CH2)m-CONH-C1-C5 alkyl; -CON-(C1-C5 alkyl)2;
    R8 represents unsubstituted phenyl; unsubstituted pyridyl; unsubstituted phenyl-C1-C5 alkyl; unsubstituted pyridyl-C1-C5 alkyl; or mono-, di- or tri-substituted phenyl, pyridyl, phenyl-C1-C5 alkyl or pyridyl-C1-C5 alkyl, whereby the substituents independently are C1-C5 alkyl, C1-C5 alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethoxy or halogen;
    R9 represents C1-C5 alkyl, C2-C5 alkenyl, cycloalkyl, cycloalkyl-C1-C5 alkyl, unsubstituted phenyl-C1-C5 alkyl; or mono-, di- or tri-substituted phenyl or phenyl-C1-C5 alkyl, whereby the substituents independently are C1-C5 alkyl, C1-C5 alkoxy, trifluoromethyl, trifluoromethoxy, difluoromethoxy or halogen;
    and optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixture of diastereoisomeric racemates, or meso forms and pharmaceutically acceptable salts thereof.
  2. Compounds according to claim 1, wherein n is the integer 0, m is the integer 0, R1, R2, R3, R4, R5, R6, R7, R8 and R9 have the meaning given in the formula (I) above and X represents oxygen.
  3. Compounds according to claim 1 and 2, wherein n is the integer 0, m is the integer 0, R5 represents methyl, R6 represents phenyl, R1, R2, R3, R4, R7, R8 and R9 have the meaning given in the formula (I) above and X represents oxygen.
  4. A compound according to any one of claims 1 to 3, selected from the group consisting of:
    1-[1-(4-Methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-(1-phenyl-ethyl)-3 -(2-propylphenyl)-urea;
    3-Biphenyl-2-yl-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl]-1-[1-phenyl-ethyl)urea;
    3-(2-Ethoxy-phenyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-(1-phenyl-ethyl)-urea;
    3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-((S)-1-phenyl-ethyl)-urea;
    3-(2-Ethoxy-phenyl)-1-[(R,S)-]-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-1-((R)-1- phenyl-ethyl)-urea;
    3-(2-Ethoxy-phenyl-1-(2-methoxy-(S)-1-phenyl-ethyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;
    3 -(2-Ethoxy-phenyl-1-(2-methoxy-(R)-1-phenyl-ethyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;
    (R)-2-{3-(2-Ethoxy-phenyl)-1-[(R,S)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-ureido}-2-phenyl-acetamide;
    (3-{1-[,3-(Ethoxy-phenyl)-1-(1-phenyl-ethyl)-ureido]-ethyl-2-oxo-2H-quinoxalin-1-yl)-acetic acid ethyl ester;
    2-{3-[3-(2-Ethoxy-phenyl)-1-(1-phenyl-ethyl)-ureidomethyl]-2-oxo-2H-quinoxalin-1yl}-acetamide;
    1-Benzyl-3-(2-ethoxy-phenyl)-1-{4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-methyl)-urea;
    1-Benzyl-3-(2-ethoxy-phenyl)-1-[1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl]-urea;
    3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl-methyl)-1-(1 -phenylethyl)-urea;
    (S)-3-(2-Ethoxy-phenyl)-1-(3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-(1-phenyl-ethyl)-urea;
    1-(6-Chloro-pyridin-3 ylmethyl)-3 (2-ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2ylmethyl)-urea;
    (S)-3-(2-Ethoxy-phenyl)-1-(2-methoxy-1-phenyl-ethyl)-1-[1-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)-ethyl]-urea;
    (R)-3-(2-Ethoxy-phenyl)-1-(2-methoxy-1-phenyl-ethyl)-1-[1-(4-methyl-3 -oxo-3,4-dihydroquinoxalin-2-yl)-ethyl]-urea;
    3-(2-Ethoxy-phenyl)-1-(2-hydroxy-(S)-1-phenyl-ethyl)-1-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-ylmethyl)-urea;
    3-(2-Ethoxy-phenyl)-1-(2-methoxy-(S)-1-phenyl-ethyl)-1-{4-methyl-3-oxo-3,4.dihydroquinoxalin-2-ylmethyl)-urea;
    3-(2-Ethoxy-phenyl)-1-(3-hydroxy-(S)-1-pheny)-propyl)-1-(4-methyl-3-oxo-3,4-dihydroquinoxalin-2-ylmethyl)-urea;
    3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-((S)-2-phenyl-propyl)-urea;
    3-(2-Ethoxy-phenyl)-1-(methyl-3-oxo-3,4-dihydro-quinoxalin-2-ylmethyl)-1-[-1-(3-trifluoromethyl-phenyl)-ethyll-urea;
    3-(2-Ethoxy-phenyl)-1-(4-methyl-3-oxo-3,4-dihydro-quïnoxalin-2-ylmethyl)-1-[-1-(4-trifluoromethyl-phenyl)-ethyl]-urea;
    N-(2-Ethoxy-phenyl)-N'-[1-(-4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-ethyl)-N'-1-phenyl- ethyl-cyanoguanidine.
  5. Pharmaceutical compositions for the treatment of disorders which are associated with the role of orexin, comprising eating disorders and sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders, containing one or more compounds of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, and usual carrier materials and adjuvants.
  6. The compounds of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, for use as medicaments for the treatment of disorders which are associated with a role of orexin, comprising eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders.
  7. Use of a compound according to any one of claims 1 to 4 in the preparation of a medicament for the treatment of disorders which are associated with a role of orexin, comprising eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders.
  8. A process for the manufacture of pharmaceutical compositions for the treatment of disorders associated with the role of orexin, eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders, containing one or more compounds as claimed in any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, as active ingredients which process comprises mixing one or more active ingredient or ingredients with pharmaceutically acceptable excipients and adjuvants in a manner known per se.
  9. Use of one or more compounds of any one of claims 1 to 4 in combination with other pharmacologically active compounds comprising other orexin receptor antagonists, with lipid lowering agents, anorectic agents, sleep inducing agents, antidepressants or other drugs beneficial for the prevention or treatment of disorders given in any one of claims 5 to 7 for the preparation of a medicament for the treatment of disorders associated with a role of orexin, comprising eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, schizophrenia or neurodegenerative disorders.
EP04729421A 2003-04-28 2004-04-26 Quinoxalin-3-one derivatives as orexin receptor antagonists Expired - Lifetime EP1620409B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04729421A EP1620409B1 (en) 2003-04-28 2004-04-26 Quinoxalin-3-one derivatives as orexin receptor antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP0304491 2003-04-28
PCT/EP2004/004374 WO2004096780A1 (en) 2003-04-28 2004-04-26 Quinoxalinone-3- one derivatives as orexin receptor antagonists
EP04729421A EP1620409B1 (en) 2003-04-28 2004-04-26 Quinoxalin-3-one derivatives as orexin receptor antagonists

Publications (2)

Publication Number Publication Date
EP1620409A1 EP1620409A1 (en) 2006-02-01
EP1620409B1 true EP1620409B1 (en) 2008-01-09

Family

ID=35529694

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04729421A Expired - Lifetime EP1620409B1 (en) 2003-04-28 2004-04-26 Quinoxalin-3-one derivatives as orexin receptor antagonists

Country Status (1)

Country Link
EP (1) EP1620409B1 (en)

Also Published As

Publication number Publication date
EP1620409A1 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
EP1751111B1 (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
EP1521583B1 (en) 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo (2,1-b)-quinazolinone derivatives
US7192950B2 (en) Benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
US7538109B2 (en) Quinoxalin-3-one derivatives as orexin receptor antagonists
AU2001260113B2 (en) 1,2,3,4-tetrahydroisoquinoline derivatives
AU2001260113A1 (en) 1,2,3,4-tetrahydroisoquinoline derivatives
AU2002240855A1 (en) Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
EP1620409B1 (en) Quinoxalin-3-one derivatives as orexin receptor antagonists
EP1274687B1 (en) 1,2,3,4- tetrahydroisoquinoline derivatives
MXPA06009833A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
KR20050018945A (en) 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO[2,1-b]-QUINAZOLINONE DERIVATIVES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004011204

Country of ref document: DE

Date of ref document: 20080221

Kind code of ref document: P

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2297413

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080409

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080609

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080409

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080430

26N No opposition filed

Effective date: 20081010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20100302

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080710

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080426

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20100427

Year of fee payment: 7

Ref country code: FR

Payment date: 20100506

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080109

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20100423

Year of fee payment: 7

Ref country code: IT

Payment date: 20100423

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080410

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100420

Year of fee payment: 7

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110426

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20111230

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110502

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111101

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004011204

Country of ref document: DE

Effective date: 20111101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110426

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110426

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20120604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110427